Mark C de Gooijer1, Ping Zhang1,2, Nishita Thota1, Isabel Mayayo-Peralta1, Levi C M Buil1, Jos H Beijnen3,4, Olaf van Tellingen5. 1. Department of Bio-Pharmacology/ Mouse Cancer Clinic, The Netherlands Cancer Institute, AKL room C1.005, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 2. Department of Neurosurgery, Qilu Hospital, Shandong University, Wenhua Xi Road 107, 250012, Jinan, People's Republic China. 3. Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute /Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. 4. Division of Drug Toxicology, Faculty of Pharmacy, Division of Biomedical Analysis, Faculty of Science, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands. 5. Department of Bio-Pharmacology/ Mouse Cancer Clinic, The Netherlands Cancer Institute, AKL room C1.005, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. o.v.tellingen@nki.nl.
Abstract
INTRODUCTION: Palbociclib is a cyclin dependent kinase (CDK) 4/6 inhibitor with nanomolar potency and was recently approved for treatment of breast cancer. The drug may also be useful in glioblastoma (GBM) and diffuse intrinsic pontine gliomas (DIPG), which often have an activated CDK4/6-retinoblastoma signaling pathway. However, GBM and DIPG spread widely into the surrounding brain, which calls for a CDK4/6 inhibitor with sufficient blood-brain barrier penetration. METHODS: We first performed in vitro transwell assays and demonstrate that palbociclib is a substrate of both P-gp and BCRP. Next, we conducted pharmacokinetic studies using wildtype, Abcg2(-/-), Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice. RESULTS: The plasma levels were about 3000 and 500 nM and similar in all genotypes at 1 and 4 h after i.v. administration of 10 mg/kg. At 4 h the brain-to-plasma ratios were 0.3 in WT and Abcg2(-/-) mice versus 5.5 and 15 in Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice, respectively. The oral bioavailability of palbociclib was high (63 %) in WT mice and increased only modestly and non-significantly in Abcg2; Abcb1a/b(-/-) mice. The plasma level after oral dosing of 150 mg/kg was already much higher than observed in patients (200-400 nM) and exceeded 2500 nM for up to 24 h. This latter dose is commonly used in preclinical studies, which calls into question their predictive value as they were conducted at dose levels causing a clinically non-relevant systemic drug exposure. CONCLUSION: Thus, the brain penetration of palbociclib is restricted by P-gp and BCRP, which may restrict the efficacy against GBM and DIPG. Moreover, preclinical studies with this agent should be conducted at a more clinically relevant dose level.
INTRODUCTION: Palbociclib is a cyclin dependent kinase (CDK) 4/6 inhibitor with nanomolar potency and was recently approved for treatment of breast cancer. The drug may also be useful in glioblastoma (GBM) and diffuse intrinsic pontine gliomas (DIPG), which often have an activated CDK4/6-retinoblastoma signaling pathway. However, GBM and DIPG spread widely into the surrounding brain, which calls for a CDK4/6 inhibitor with sufficient blood-brain barrier penetration. METHODS: We first performed in vitro transwell assays and demonstrate that palbociclib is a substrate of both P-gp and BCRP. Next, we conducted pharmacokinetic studies using wildtype, Abcg2(-/-), Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice. RESULTS: The plasma levels were about 3000 and 500 nM and similar in all genotypes at 1 and 4 h after i.v. administration of 10 mg/kg. At 4 h the brain-to-plasma ratios were 0.3 in WT and Abcg2(-/-) mice versus 5.5 and 15 in Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice, respectively. The oral bioavailability of palbociclib was high (63 %) in WT mice and increased only modestly and non-significantly in Abcg2; Abcb1a/b(-/-) mice. The plasma level after oral dosing of 150 mg/kg was already much higher than observed in patients (200-400 nM) and exceeded 2500 nM for up to 24 h. This latter dose is commonly used in preclinical studies, which calls into question their predictive value as they were conducted at dose levels causing a clinically non-relevant systemic drug exposure. CONCLUSION: Thus, the brain penetration of palbociclib is restricted by P-gp and BCRP, which may restrict the efficacy against GBM and DIPG. Moreover, preclinical studies with this agent should be conducted at a more clinically relevant dose level.
Authors: Barbara S Paugh; Alberto Broniscer; Chunxu Qu; Claudia P Miller; Junyuan Zhang; Ruth G Tatevossian; James M Olson; J Russell Geyer; Susan N Chi; Nasjla Saba da Silva; Arzu Onar-Thomas; Justin N Baker; Amar Gajjar; David W Ellison; Suzanne J Baker Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin Journal: Cell Date: 2013-10-10 Impact factor: 41.582
Authors: Ruben Niesvizky; Ashraf Z Badros; Luciano J Costa; Scott A Ely; Seema B Singhal; Edward A Stadtmauer; Nisreen A Haideri; Abdulraheem Yacoub; Georg Hess; Suzanne Lentzsch; Ivan Spicka; Asher A Chanan-Khan; Marc S Raab; Stefano Tarantolo; Ravi Vij; Jeffrey A Zonder; Xiangao Huang; David Jayabalan; Maurizio Di Liberto; Xin Huang; Yuqiu Jiang; Sindy T Kim; Sophia Randolph; Selina Chen-Kiang Journal: Leuk Lymphoma Date: 2015-05-15
Authors: E M Kemper; W Leenders; B Küsters; S Lyons; T Buckle; A Heerschap; W Boogerd; J H Beijnen; O van Tellingen Journal: Eur J Cancer Date: 2006-10-05 Impact factor: 9.162
Authors: Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz Journal: Clin Cancer Res Date: 2011-11-16 Impact factor: 12.531
Authors: Donglu Zhang; Cornelis E C A Hop; Gabriela Patilea-Vrana; Gautham Gampa; Herana Kamal Seneviratne; Jashvant D Unadkat; Jane R Kenny; Karthik Nagapudi; Li Di; Lian Zhou; Mark Zak; Matthew R Wright; Namandjé N Bumpus; Richard Zang; Xingrong Liu; Yurong Lai; S Cyrus Khojasteh Journal: Drug Metab Dispos Date: 2019-07-02 Impact factor: 3.922
Authors: Yogesh T Patel; Abigail Davis; Suzanne J Baker; Olivia Campagne; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2019-05-11 Impact factor: 3.333
Authors: Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist Journal: Curr Pharmacol Rep Date: 2016-11-09
Authors: Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann Journal: Transl Res Date: 2017-08-10 Impact factor: 7.012